Global Meningococcal Vaccines Market Size, Share 2021-2026

According to IMARC Group’s latest report, titled “Meningococcal Vaccines Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the global meningococcal vaccines market reached a value of US$ 2.8 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 9.5% during 2021-2026.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

The meningococcal vaccine includes a biological substance formulated to prevent meningitis that occurs when the liquid surrounding the brain and spinal cords become infected. The meningococcal vaccines can broadly be categorized into conjugate, polysaccharide, and subcapsular meningococcal vaccines. They are widely administered to infants, children and adults to immunize them against invasive ailments and meningococcal bacteria. Once the vaccine is dispensed, antibodies are formed to fight the bacteria and create an immune response to preclude the infection in the future.

Request Free Sample Report: https://www.imarcgroup.com/meningococcal-vaccines-market/requestsample

Market Trends

The growing prevalence of meningococcal diseases is primarily driving the market for meningococcal vaccines. Furthermore, the increasing health consciousness among the masses and the rising adoption of routine immunization are also positively influencing the market. The meningococcal vaccine helps in preventing the disease and minimizing the long-term effects, such as neurological damage, temporary or permanent deafness, and loss of vision and motor skills. Additionally, the government bodies across various nations are launching extensive public health programs for focusing on the immunization of special risk groups, such as tourists and military personnel, to contain the spread of infections. All of the above-mentioned factors will continue to drive the market for meningococcal vaccines in the coming years.

Ask Analyst and Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/meningococcal-vaccines-market

List of Key Companies Covered in this Market Report:

GlaxoSmithKline Plc
Hualan Biological Engineering Inc.
Incepta Pharmaceuticals Limited
Novartis AG
Pfizer Inc.
Sanofi S.A.
Serum Institute of India Ltd.
Walvax Biotechnology Co. Ltd.

The report has segmented the market on the basis of vaccine type, composition, vaccine serotype, distribution channel, end-user and geography.

Breakup by Vaccine Type:

Conjugate
Polysaccharide
Subcapsular

Breakup by Composition:

Mono Vaccines
Combination Vaccines

Breakup by Vaccine Serotype:

MenACWY
MenB & Manic
MenC
MenA
MenAC
Others

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Institutional Sales
Others

Breakup by End User:

Pediatric
Adult

Breakup by Geography:

North America (U.S. & Canada)
Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
Latin America (Brazil, Mexico)
Middle East & Africa

Key highlights of the report:

Market Performance (2015-2025)
Market Outlook (2021- 2026)
Porter’s Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
Follow us on Twitter: https://twitter.com/ImarcServices

dofollow

Share
LEAVE A REPLY
Related Post
COMMENTS
  1. author
    27 Aug 2019
    Tomas Mandy

    Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius

    1. author
      27 Aug 2019
      Britney Millner

      Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius

  2. author
    27 Aug 2019
    Simon Downey

    Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius